MTOR and autosomal dominant polycystic kidney disease: Double treatment with the mTOR inhibitor rapamycin and the cAMP inhibitor 2-Chloro-N(6)-(3-iodobenzyl) adenosine-5’-N-methylcarboxamide (Cl-IB-MECA) may have synergistic effects on the inhibition of cell proliferation in ADPKD [80].